KURA — Kura Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422143 ·
Last close
$11.45
Market Cap
$1.02B
52W High
$12.22
52W Low
$8.39
ADV30
1,901,739
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 18,265,000 | 18,003,000 | -78,815,000 | -73,333,000 | 652,551,000 | 39,083,000 | 544,668,000 |
| Dec 2025 | 17,336,000 | — | -86,268,000 | -80,999,000 | 738,363,000 | 149,099,000 | 564,228,000 |
| Sep 2025 | 20,750,000 | — | -79,997,000 | -74,116,000 | 649,381,000 | 95,287,000 | 406,839,000 |
| Jun 2025 | 15,288,000 | — | -72,666,000 | -66,122,000 | 682,425,000 | 81,948,000 | 376,939,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,985,000
Investing CF
$64,080,000
Financing CF
$1,719,000
CapEx
$-6,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.35
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,247,421,000
Inventory
$843,000
Receivables
$9,348,000
ST Investments
$541,740,000
EBIT TTM
$-293,025,000
Pretax Income TTM
$-294,491,000
Interest Exp TTM
$1,466,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,639,000
EBITDA
$-316,600,000
Free Cash Flow
$-129,832,496
Enterprise Value
$515,844,320
Total Cash
$580,822,976
Total Debt
$24,273,000
Shares Out
88,774,365
Trailing EPS
$-3.35
Book Value
$1.22
ROE
-124.7%
ROA
-28.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,482,000 | -303,631,000 | -278,666,000 | 738,363,000 | 564,228,000 | — | -64,058,000 |
| Dec 2024 | 53,883,000 | -193,195,000 | -173,983,000 | 760,159,000 | 346,519,000 | — | 134,317,000 |
| Dec 2023 | 0 | -165,804,000 | -152,631,000 | 448,935,000 | 51,662,000 | — | -124,824,000 |
| Dec 2022 | 0 | -139,865,000 | -135,840,000 | 456,306,000 | 36,028,000 | — | -110,062,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVA | Inventiva S.A. | $1.02B | $4.30 | — |
| OPK | OPKO HEALTH, INC. | $1.02B | $1.35 | — |
| AVTX | Avalo Therapeutics, Inc. | $1.01B | $19.21 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $1.01B | $12.61 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.00B | $36.61 | — |
News headlines (Yahoo Finance, 1h cache)
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
2026-07-07 22:09 · Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-03 11:30 · Yahoo
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
2026-06-30 13:06 · Yahoo
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
2026-06-11 12:02 · Yahoo
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions
2026-06-06 08:07 · Yahoo
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
2026-06-03 10:53 · Yahoo
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
2026-06-02 12:32 · Yahoo
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
2026-05-26 10:02 · Yahoo
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
2026-05-19 20:02 · Yahoo
Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
2026-05-17 13:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.